IL4R and Alzheimer disease: Our data show that targeting of IL‐4Rα after 6 months not only improves the clinical symptoms of AD but also results in significant systemic changes of the T cell subset clustering and their cytokine production profiles and its associated outcome parameters like total and specific IgE levels and eosinophils.